FBXO6 as A Drug Target for Various Diseases (G26270)

Target Name: FBXO6

NCBI ID: G26270

FBXO6

FBXO6 as A Drug Target for Various Diseases

FBXO6 (Fbx6b) is a protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. It is a member of the Fbxo6 gene family, which encodes a protein involved in the regulation of actinin, a protein that is important for cell-cell adhesion and maintenance of tissue structure.

Recent studies have identified FBXO6 as a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because the Fbxo6 gene family has been shown to be involved in the regulation of a wide range of cellular processes, including cell adhesion, migration, and invasion.

One of the key reasons for the potential of FBXO6 as a drug target is its involvement in the regulation of actinin. Actinin is a protein that is involved in the regulation of cell-cell adhesion, and is critical for the maintenance of tissue structure and the development and maintenance of various tissues, including blood vessels, neurons, and epithelial cells.

Studies have shown that FBXO6 plays a role in the regulation of actinin, by interacting with the protein F-actinin. This interaction between FBXO6 and F-actinin allows for the regulation of actinin levels, and is involved in the development and maintenance of various tissues.

In addition to its role in actinin regulation, FBXO6 has also been shown to be involved in the regulation of several other cellular processes, including cell migration and invasion. These functions are important for the development and progression of many diseases, including cancer and neurodegenerative disorders.

FBXO6 has also been shown to be involved in the regulation of various signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and is a key factor in the development and progression of many diseases.

The potential of FBXO6 as a drug target is based on its involvement in a wide range of cellular processes, including actinin regulation, cell migration and invasion, and TGF-β signaling. These functions make it an attractive target for the development of new treatments for a variety of diseases.

Protein Name: F-box Protein 6

Functions: Substrate-recognition component of some SCF (SKP1-CUL1-F-box protein)-type E3 ubiquitin ligase complexes. Involved in endoplasmic reticulum-associated degradation pathway (ERAD) for misfolded lumenal proteins by recognizing and binding sugar chains on unfolded glycoproteins that are retrotranslocated into the cytosol and promoting their ubiquitination and subsequent degradation. Able to recognize and bind denatured glycoproteins, which are modified with not only high-mannose but also complex-type oligosaccharides. Also recognizes sulfated glycans. Also involved in DNA damage response by specifically recognizing activated CHEK1 (phosphorylated on 'Ser-345'), promoting its ubiquitination and degradation. Ubiquitination of CHEK1 is required to insure that activated CHEK1 does not accumulate as cells progress through S phase, or when replication forks encounter transient impediments during normal DNA replication

The "FBXO6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBXO6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets